| Size | Price | Stock | Qty |
|---|---|---|---|
| 10g |
|
||
| 25g |
|
||
| Other Sizes |
| Targets |
The primary molecular target of L-Allylglycine is glutamate decarboxylase (GAD, EC 4.1.1.15), which catalyzes the conversion of L-glutamate to gamma-aminobutyric acid (GABA). By inhibiting GAD activity, this compound reduces GABA levels in the central nervous system, leading to decreased inhibitory neurotransmission and convulsant effects.
|
|---|---|
| ln Vitro |
Commercial ergot supplements have been made from amino acids and their derivatives. They affect the release of anabolic hormones, the availability of fuel for activity, the ability to think clearly under pressure, and the prevention of muscular damage brought on by exertion. They are regarded as advantageous synergistic food ingredients [1].
In vitro studies demonstrate that L-Allylglycine hydrochloride inhibits glutamate decarboxylase activity in brain homogenates and purified enzyme preparations. The compound acts as an irreversible inhibitor, binding to the active site and blocking the decarboxylation of glutamate, thereby reducing GABA biosynthesis in cell-free systems and neuronal cultures. |
| ln Vivo |
In vivo, L-Allylglycine hydrochloride (150 mg/kg, intraperitoneal injection or 200 ug intranigral injection, single dose) induces convulsive behaviors in Sprague-Dawley rat models. The compound reduces GABA content in the hippocampus, cortex, and cerebellum, leading to running fits, partial rigidity, and full convulsions in treated animals.
|
| Enzyme Assay |
Cell-free GAD inhibition assays are performed using rat brain homogenates or purified enzyme in reaction buffer containing L-[14C]glutamate, pyridoxal phosphate (cofactor), and varying concentrations of compound (0.1-1000 uM). Reactions are incubated at 37degC for 30 minutes, stopped with HCl, and 14CO2 trapped on filter paper for scintillation counting to determine IC50 values.
|
| Cell Assay |
Cell-based assays for GAD inhibition utilize primary neuronal cultures or brain slices. Cells are treated with L-Allylglycine (10-500 uM) for 2-24 hours, then lysed for GABA quantification via HPLC with electrochemical detection or enzymatic assay. Alternatively, electrophysiological recordings measure alterations in GABAergic synaptic transmission.
|
| Animal Protocol |
Animal convulsant studies are conducted in Sprague-Dawley rats (200-300 g). Animals receive a single intraperitoneal injection of L-Allylglycine hydrochloride (150 mg/kg) or intranigral microinjection (200 ug). After administration, animals are observed for 60-120 minutes for latency to convulsion, seizure severity scores, and brain region GABA content measurements via LC-MS/MS.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of L-Allylglycine in rodents include rapid absorption after intraperitoneal administration (Tmax ~30 minutes), brain penetration (brain-to-plasma ratio ~0.3-0.5), plasma half-life of 1-2 hours, volume of distribution approximately 0.6 L/kg, and elimination primarily via urine as unchanged drug or metabolites.
|
| Toxicity/Toxicokinetics |
Toxicological evaluation indicates that L-Allylglycine hydrochloride exhibits convulsant activity as a primary toxic effect. Acute toxicity studies show LD50 values around 200-300 mg/kg in mice (intraperitoneal). Chronic exposure may lead to sustained GABA depletion and neurotoxicity. The compound is not intended for therapeutic use due to its pro-convulsant properties.
|
| References |
[1]. Luckose F, et al. Effects of amino acid derivatives on physical, mental, and physiological activities. Crit Rev Food Sci Nutr. 2015;55(13):1793-1144.
|
| Additional Infomation |
This compound is a solid with molecular formula C5H10ClNO2 and molecular weight 151.59. It is soluble in DMSO (100 mg/mL) and stable at 4degC under nitrogen. Applications include studying GABAergic neurotransmission, epilepsy models, and enzyme inhibition mechanisms. For research use only, not for human administration.
|
| Molecular Formula |
C5H10CLNO2
|
|---|---|
| Molecular Weight |
151.59
|
| Exact Mass |
151.04
|
| CAS # |
195316-72-4
|
| PubChem CID |
44630067
|
| Appearance |
White to off-white solid powder
|
| Melting Point |
283 °C (dec.)
|
| Index of Refraction |
-10 ° (C=2, H2O)
|
| LogP |
1.476
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
9
|
| Complexity |
101
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
C=CC[C@@H](C(=O)O)N.Cl
|
| InChi Key |
DIDZZOWASZMNQW-WCCKRBBISA-N
|
| InChi Code |
InChI=1S/C5H9NO2.ClH/c1-2-3-4(6)5(7)8;/h2,4H,1,3,6H2,(H,7,8);1H/t4-;/m0./s1
|
| Chemical Name |
(2S)-2-aminopent-4-enoic acid;hydrochloride
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 100 mg/mL (659.67 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (16.49 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (16.49 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (16.49 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 6.5967 mL | 32.9837 mL | 65.9674 mL | |
| 5 mM | 1.3193 mL | 6.5967 mL | 13.1935 mL | |
| 10 mM | 0.6597 mL | 3.2984 mL | 6.5967 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
